Quest Diagnostics Incorporated (NYSE:DGX) expected to pay $0.40 on Oct 19, 2016

Quest Diagnostics Incorporated (NYSE:DGX) is expected to pay $0.40 on Oct 19, 2016. The indicated annual dividend is $1.60. Shareholders owning the stock before Sep 30, 2016 will be eligible to receive the payout. Based on Quest Diagnostics Incorporated’s current price of $84.94, the dividend is 0.47%. This dividend’s record date is Oct 4, 2016 and the announcement date is Aug 17, 2016. The stock increased 0.07% or $0.06 during the last trading session, hitting $84.94. Quest Diagnostics Inc (NYSE:DGX) has risen 27.31% since February 25, 2016 and is uptrending. It has outperformed by 16.05% the S&P500.

Quest Diagnostics Incorporated is a well-known provider of diagnostic information services. The company has a market cap of $11.85 billion. The Firm operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. It has a 14.86 P/E ratio. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations , integrated delivery networks (IDNs), other commercial laboratories, employers and others.

Insitutional Activity: The institutional sentiment increased to 1.07 in Q2 2016. Its up 0.02, from 1.05 in 2016Q1. The ratio increased, as 35 funds sold all Quest Diagnostics Inc shares owned while 173 reduced positions. 55 funds bought stakes while 168 increased positions. They now own 124.00 million shares or 7.05% less from 133.41 million shares in 2016Q1.

Healthcare Value Capital Llc holds 6.53% of its portfolio in Quest Diagnostics Inc for 66,208 shares. Healthcor Management L.P. owns 1.15 million shares or 5.11% of their US portfolio. Moreover, Randolph Co Inc has 4.9% invested in the company for 234,100 shares. The California-based Poplar Forest Capital Llc has invested 4.54% in the stock. Sarissa Capital Management Lp, a Connecticut-based fund reported 159,000 shares.

Out of 8 analysts covering Quest Diagnostics (NYSE:DGX), 1 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 13% are positive. Quest Diagnostics has been the topic of 12 analyst reports since October 16, 2015 according to StockzIntelligence Inc. Citigroup initiated the stock on September 9 with “Neutral” rating. Jyske Bank downgraded the shares of DGX in a report on June 24 to “Sell” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment